Adjuvant Pembrolizumab in High-Risk Muscle-Invasive Urothelial Carcinoma summary by Maria Natalia Gandur Quiroga

Maria Natalia Gandur Quiroga shared a post on X:

“Adjuvant Pembrolizumab in High-Risk Muscle-Invasive Urothelial Carcinoma

Study compared adjuvant pembrolizumab vs. observation in 702 patients.
Median disease-free survival:

• Pembrolizumab: 29.6 months

• Observation: 14.2 months (HR: 0.73, p=0.003)
Benefit seen across all PD-L1 statuses and prior neoadjuvant therapy.
Grade 3+ adverse events in 50.7% of pembrolizumab group.

Clinical Implications:

• Pembrolizumab significantly lengthens disease-free survival in high-risk patients.
• PD-L1 status is not predictive for treatment selection.”

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Authors: Andrea B. Apolo, et al.

Source: Maria Natalia Gandur Quiroga/X

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.